Use of Rituximab in Two Unusual Antibody-Mediated Autoimmune Disorders

Wisnieski J.J. , Baer A.N. , Christensen J. . Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients. Medicine (Baltimore) 1995; 74: 24–41

Arioglu E. , Andewelt A. , Diabo C. , Bell M. , Taylor S.I. , Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002; 81: 87–100

Grillo-Lopez A.J. , Hedrick E. , Rashford M. , Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002; 29(suppl 2): 105–12

Edwards J.C. , Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205–11

Perrotta S. , Locatelli F. , La Manna A. , Cennamo L. , De Stefano P. , Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 116: 465–7

Chaiwatanatorn K. , Lee N. , Grigg A. , Filshie R. , Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913–18